Bicara Therapeutics Q2 Earnings Call Highlights

Key Points

• FICERA’s pivotal FORTIFI-HN01 trial remains on track for substantial enrollment by the end of 2026, with an interim analysis planned for mid-2027. Bicara highlighted three-year data suggesting roughly one-third of patients were alive at the 1,500-milligram weekly dose, while noting the results are based on a small cohort.
• Bicara is preparing for a leadership transition in January 2027, when President and COO Ryan Cohlhepp will become CEO and current CEO Claire Mazumdar will move to vice chair and strategic advisor. The company is also adding new executives across operations, business development, finance and legal functions.
• The company began the FORTIFI-FLEX study to evaluate a loading dose followed by every-three-week maintenance dosing and plans additional colorectal cancer cohorts. Bicara ended Q2 with approximately $497 million in cash and marketable securities, which it expects to fund operations into the first half of 2029 despite rising trial and commercialization expenses.

Bicara Therapeutics NASDAQ: BCAX used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of ficerafusp alfa, or FICERA, while reaffirming its cash runway into the first half of 2029.

The company is advancing FICERA in the Phase III FORTIFI-HN01 trial for first-line recurrent or metastatic HPV-negative head and neck squamous cell cancer. Management said it remains on track for substantial enrollment by the end of 2026, positioning the company for a planned interim analysis in mid-2027 and a potential accelerated-approval path.

Leadership Transition Set for January

Chief Executive Officer Claire Mazumdar will transition at the beginning of 2027 to vice chair of the board and strategic advisor. Ryan Cohlhepp, currently president and chief operating officer, will become president and CEO.

Mazumdar said the succession plan had been discussed since the company’s founding and comes as Bicara prepares for potential commercialization. She said Cohlhepp’s experience includes oncology drug launches, management of Takeda’s U.S. oncology portfolio and commercial leadership across solid and hematologic tumors.

“This transition is not about changing our direction,” Cohlhepp said. “It’s about building upon a foundation that has been intentionally created over many years.”

Other planned leadership changes include:

• Tanya Green, currently chief development officer, will become chief operating officer in January.
• Jenna Cohen, currently chief corporate affairs officer, will become chief business officer in January.
• Greg Shiferman will join the company as chief legal officer at the end of August.
• Jenn Larson will succeed Chief Financial Officer Ivan Hyep effective the day after the earnings call.

Hyep, an early executive at Bicara, helped lead more than $800 million in capital raises and guided the company’s transition to the public markets, Mazumdar said. The company also recently added Jeremy Bender and Christy Oliger to its board.

FORTIFI-HN01 Enrollment and Clinical Data

Bicara said more than 200 sites are active in FORTIFI-HN01 and that investigator engagement has remained strong. The trial is a major priority as the company seeks to complete substantial enrollment this year.

At the American Society of Clinical Oncology meeting in May, Bicara presented three-year follow-up data from approximately 90 patients across three dose cohorts in first-line recurrent or metastatic HPV-negative head and neck cancer. At the company’s pivotal 1,500-milligram weekly dose, management said an estimated one in three patients was alive at three years, which it said was approximately double the survival rate seen in retrospective analyses of standard-of-care pembrolizumab in HPV-negative patients.

Mazumdar said the ASCO data demonstrated “unprecedented depth and duration of response,” while Cohlhepp said the results reinforced FICERA’s potential to become a best-in-class treatment in the setting. Management also highlighted what it described as a consistent safety profile over the follow-up period.

During the question-and-answer session, Mazumdar said the company has received positive feedback from investigators following the ASCO presentation, including on response durability and tolerability. She said the company expects depth of response, six-month durability and the totality of the data to be important considerations at the planned interim analysis, rather than response rates alone.

Alternative Dosing Study Underway

Bicara has initiated FORTIFI-FLEX, an alternative-dosing study intended to support a loading-dose and every-three-week maintenance regimen for FICERA. The company said it designed and activated the study after presenting exploratory every-two-week cohort data earlier in 2026.

Management said the goal is to have FORTIFI-FLEX data available by the time of a potential U.S. approval, potentially supporting a streamlined regimen at launch. Mazumdar said the study will compare the alternative regimen with the 1,500-milligram weekly regimen, focusing on comparability in durability of response after the loading phase.

Green said Bicara is seeking to limit interference with enrollment in FORTIFI-HN01. About one-third of FORTIFI-FLEX sites will overlap with the pivotal trial, with enrollment staged across Europe, Latin America, Asia-Pacific and the U.S. to keep FORTIFI-HN01 as the priority.

Broader Development Plans and Financial Position

Beyond the pivotal head and neck cancer program, Bicara is pursuing signal-seeking cohorts in third-line or later microsatellite-stable colorectal cancer. The company expects to report data by year-end from two open-label cohorts of about 20 patients each: one evaluating FICERA as monotherapy and one evaluating it with pembrolizumab.

Mazumdar said the company expects the early colorectal update to provide short-term safety and efficacy information. Management is also considering biomarker and patient-selection questions, including potential differences between left-sided and right-sided colorectal cancer, and said it has explored combinations with RAS inhibitors.

Bicara said it has previously established proof of concept for FICERA in cutaneous squamous cell carcinoma and anal canal cancer, and it continues to evaluate opportunities in locally advanced head and neck cancer and other tumor types.

For the second quarter, Hyep said total operating expenses increased from the prior-year period due to clinical operations, development and manufacturing costs related to FORTIFI-HN01, as well as higher personnel costs and stock-based compensation. The company expects operating expenses to rise sequentially through the rest of 2026 as it invests in the pivotal trial, FORTIFI-FLEX, technical operations, medical affairs and commercial launch preparation.

Bicara ended the quarter with approximately $497 million in cash equivalents and marketable securities. Hyep said the company expects that capital to fund operations into the first half of 2029, including the pivotal program through a primary overall-survival analysis, a planned regulatory filing, initial commercial and medical infrastructure, alternative-dosing development and manufacturing activities.

About Bicara Therapeutics (NASDAQ:BCAX)

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source